SKLB-D18 exhibited superior anti-tumor activity over the clinical ERK1/2 inhibitor BVD-523 by inhibiting ERK1/2 activity and ERK5-driven resistance, providing a potential clinical monotherapy strategy to overcome resistance encountered in targeted ERK1/2 therapy for TNBC. Here, MAPK7 is linked to neoplasm.